TCG Crossover (TCGX), a prominent life sciences investment firm, successfully closed its third fund at $1.3 billion, raising total capital to $3.1 billion across multiple funds. The firm aims to capitalize on attractive valuations across private and public biotech equities, navigating market headwinds and volatility. According to Chen Yu, TCGX’s managing partner, the fund focuses on identifying compelling opportunities in biotech innovation despite macroeconomic uncertainties, reflecting investor confidence in sector fundamentals.